StockData
AIM ImmunoTech Inc. logo

AIM ImmunoTech Inc. (AIM) stock

AIMNYSEBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 12, 2026Score 2/30
$0.15+0.00 (+0.13%)

Close on Nov 12, 2026Market cap $4.52MP/E –Yield –

Earnings

AIM ImmunoTech's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
–
Not yet scheduled
Revenue, Q2 FY2026
–
EPS, Q2 FY2026
-$0.43
Latest guidance
None
No outlook given in releases

Quarterly results

Revenue and earnings per share from each of AIM ImmunoTech's earnings releases, newest first

QuarterReportedRevenueYoYEPSSource
Q2 FY2026ended Jun 30, 2026Aug 10, 2026before the open––-$0.43Release
Q1 FY2026ended Mar 31, 2026May 19, 2026before the open–––Release
Q1 FY2020ended Mar 31, 2020Apr 16, 2020during market hours–––Filing
Q3 FY2019ended Sep 30, 2019Oct 7, 2019before the open–––Filing
Q2 FY2017ended Jun 30, 2017Aug 15, 2017before the open–––Filing
Q1 FY2017ended Mar 31, 2017Apr 3, 2017during market hours–––Filing
Q3 FY2016ended Sep 30, 2016Nov 15, 2016during market hours–––Filing
Q2 FY2016ended Jun 30, 2016Aug 15, 2016during market hours–––Filing
Q1 FY2016ended Mar 31, 2016May 16, 2016during market hours–––Filing
Q4 FY2015ended Dec 31, 2015Mar 30, 2016before the open–––Filing

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Guidance

AIM ImmunoTech has not given guidance in its releases

Many companies give their outlook only on the conference call or not at all. When AIM ImmunoTech puts a forecast in an earnings release, it is listed here with the exact sentence.

Press releases

Releases AIM ImmunoTech filed with the SEC as exhibits to Form 8-K or 6-K

  1. 8-K exhibit EX-99.1
    Update
  2. ImmunoTech Highlights Ampligen® Opportunity to Potentially Extend Benefits of RAS-Targeted Therapies in Pancreatic Cancer
    Update
  3. Is Force Protection: Ready Today, Prepared for Tomorrow
    Update
  4. DRAFT NOT FOR IMMEDIATE RELEASE
    Results
  5. AIM ImmunoTech Regains NYSE American Compliance,
    News
  6. ImmunoTech Announces $2.65 Million Financing Priced At-Market under NYSE American Rules
    News
  7. ImmunoTech Releases Virtual Investor ‘What This Means’ Video Segment Discussing Ampligen’s Potential in Ebola Virus
    Update
  8. 8-K exhibit EX-99.2
    Update
  9. ImmunoTech Announces Significant Increase in Stockholder Equity and Extension of Promissory Note Maturity Date to June 2027, Enhancing
    Results
  10. ImmunoTech Posts Virtual Investor Key Opinion Leader Segment Spotlighting Ampligen Breakthrough Data in Pancreatic Cancer
    Update
  11. 8-K exhibit EX-99.1
    Update
  12. Year-End Interim Clinical Progress Update
    Update
  13. ImmunoTech Reports Positive Year-End Interim Clinical Progress from Phase 2 Study
    Update
  14. of Change and Modification of Class E Common Stock Purchase Warrants
    Update
  15. of Change and Modification of Class F Common Stock Purchase Warrants
    Update

See a number that looks wrong?